These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6110951)

  • 21. The effect of beta-lactam antibiotics on the growth curves of Bacteroides fragilis, obtained with the MS-2 system.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Labbé M; Crokaert F
    J Antimicrob Chemother; 1981 Sep; 8(3):219-24. PubMed ID: 6457023
    [No Abstract]   [Full Text] [Related]  

  • 22. Absence of beta-lactamase-inducing effect of moxalactam.
    Mouton RP; van Gestel M; Bongaerts GP
    Rev Infect Dis; 1982; 4 Suppl():S527-8. PubMed ID: 6218562
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro activity of moxalactam against anaerobic bacteria.
    Gilchrist MJ; Washington JA
    Rev Infect Dis; 1982; 4 Suppl():S511-5. PubMed ID: 6218560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibacterial activity of the cephamycin cefotetan: an in-vitro comparison with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():67-72. PubMed ID: 6404881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro activity and beta-lactamase stability of Sch 29482, a penem antibiotic. Comparisons with ceftazidime and moxalactam.
    Dornbusch K; Adamsson L; Gezelius L; Hallander H
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():113-21. PubMed ID: 6460739
    [No Abstract]   [Full Text] [Related]  

  • 26. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Hanslo D; King A; Shannon K; Warren C; Phillips I
    J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic.
    Snepar R; Poporad G; Romano J; Levison ME
    Antimicrob Agents Chemother; 1981 Nov; 20(5):642-7. PubMed ID: 6459763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxalactam: an oxa-beta-lactam antibiotic that inactivates beta-lactamases.
    Labia R
    Rev Infect Dis; 1982; 4 Suppl():S529-35. PubMed ID: 6218563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Moxalactam: a new group of beta-lactams].
    Fourtillan JB
    Sem Hop; 1983 Jun; 59(26):1947-8. PubMed ID: 6310783
    [No Abstract]   [Full Text] [Related]  

  • 30. Paradoxic and tolerant effects of moxalactam on Staphylococcus aureus.
    Nelson RE; Washington JA
    J Infect Dis; 1981 Aug; 144(2):178. PubMed ID: 6456314
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of different statistical methodologies on the evaluation of the in-vitro MICs for Bacteroides fragilis of selected cephalosporins and cephamycins.
    White RL; Kays MB; Friedrich LV; Del Bene VE
    J Antimicrob Chemother; 1993 Jan; 31(1):57-64. PubMed ID: 8444675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of in-vitro activity of latamoxef (moxalactam) and ceftazidime against Pseudomonas and Enterobacteriaceae resistant to first generation cephalosporins.
    Chattopadhyay B; Hall I; Curnow SR
    J Antimicrob Chemother; 1983 Feb; 11(2):200-1. PubMed ID: 6219982
    [No Abstract]   [Full Text] [Related]  

  • 33. A clinical isolate of Bacteroides fragilis from Hungary with high-level resistance to imipenem.
    Sóki J; Edwards R; Urbán E; Fodor E; Nagy E
    J Med Microbiol; 2001 Jan; 50(1):107. PubMed ID: 11192497
    [No Abstract]   [Full Text] [Related]  

  • 34. Moxalactam: the first of a new class of beta-lactam antibiotics.
    Webber JA; Yoshida T
    Rev Infect Dis; 1982; 4 Suppl():S496-500. PubMed ID: 6218558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefotetan activity against Gram-negative aerobes and anaerobes.
    Moosdeen F; Maskell J; Philpott-Howard J; Williams JD
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():59-65. PubMed ID: 6601657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity and beta-lactamase stability of moxalactam and other selected cephalosporin antibiotics.
    Vuye A
    Arzneimittelforschung; 1981; 31(8):1290-5. PubMed ID: 6457607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and degree of expression of the carbapenemase gene (cfiA) among clinical isolates of Bacteroides fragilis in Nottingham, UK.
    Edwards R; Hawkyard CV; Garvey MT; Greenwood D
    J Antimicrob Chemother; 1999 Feb; 43(2):273-6. PubMed ID: 11252334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility to cefazedone and cefazolin and production of beta-lactamase in in Bacteroides fragilis and other species of Bacteroidaceae.
    Werner H; Krasemann C; Ungerechts J
    Arzneimittelforschung; 1979; 29(2a):388-92. PubMed ID: 314805
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Oct; 8(4):323-31. PubMed ID: 6271726
    [No Abstract]   [Full Text] [Related]  

  • 40. [Activity of cefotetan against anaerobic bacteria].
    Sedallian A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):643-4. PubMed ID: 2877431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.